• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

CDRH director Burlington to step down

Article

After 18 years at the Food and Drug Administration, Dr. Bruce Burlington will leave the agency in March, FDA Commissioner Dr. Jane Henney announced last month. Burlington is leaving his position at the FDA to head regulatory affairs at Wyeth-Ayerst

After 18 years at the Food and Drug Administration, Dr. Bruce Burlington will leave the agency in March, FDA Commissioner Dr. Jane Henney announced last month. Burlington is leaving his position at the FDA to head regulatory affairs at Wyeth-Ayerst Pharmaceuticals in Philadelphia.

After joining the FDA in 1981, Burlington held several posts before becoming director of the Center for Devices and Radiological Health (CDRH) in 1993 (SCAN 5/19/93). He is credited with streamlining the agency's 510(k) review process, eliminating its product review backlog, and dramatically cutting review times.

In December, the CDRH released product review data that indicate how far the center has come since the dark days of the mid-1990s. In 1998, the CDRH had the shortest review time for pre-market approval (PMA) applications in a decade: From October 1997 to September 1998, the agency cleared 33% of PMAs in less than 180 days, and 63% in less than a year. The average total review time for 510(k) applications for the period was 114 days, an improvement over 130 days in fiscal year 1997 and 145 days in 1996. Almost 60% of 510(k) applications received by the agency during fiscal year 1998 were cleared within 90 days.

Related Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.